SEC Company Response from TuHURA Biosciences, (HURA) — Aug 9, 2019
TuHURA Biosciences, Inc./NV (HURA) (CIK 0001498382)
Date: Aug. 9, 2019 · CIK: 0001498382 · Accession: 0001213900-19-015194
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-232931
Letter
Re: DelMar Pharmaceuticals, Inc.
August 9, 2019
VIA EDGAR
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Registration Statement on Form S-1, as amended (File No. 333-232931)
Ladies and Gentlemen:
As the underwriter of the proposed offering of DelMar Pharmaceuticals, Inc. (the “Company”), we hereby join the Company’s request for acceleration of the above-referenced Registration Statement, requesting effectiveness for 5:00 p.m., Eastern Time, on August 13, 2019, or as soon thereafter as is practicable.
The undersigned advise that they have complied and will continue to comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very truly yours,
Maxim Group LLC
Show Raw Text
CORRESP
1
filename1.htm
August 9, 2019
VIA EDGAR
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Re:
DelMar Pharmaceuticals, Inc.
Registration Statement on Form S-1, as amended (File
No. 333-232931)
Ladies and Gentlemen:
As
the underwriter of the proposed offering of DelMar Pharmaceuticals, Inc. (the “Company”), we hereby join
the Company’s request for acceleration of the above-referenced Registration Statement, requesting effectiveness for 5:00
p.m., Eastern Time, on August 13, 2019, or as soon thereafter as is practicable.
The
undersigned advise that they have complied and will continue to comply with Rule 15c2-8 under the Securities Exchange Act of 1934,
as amended.
Very truly yours,
Maxim Group LLC
By:
/s/ Clifford A. Teller
Name: Clifford A. Teller
Title: Head of Investment Banking, Executive Managing Director